Virus-like particle display of HER2 induces potent anti-cancer responses

Arianna Palladini; Susan Thrane; Christoph M Janitzek; Jessica Pihl; Stine B Clemmensen; Willem Adriaan de Jongh; Thomas M Clausen; Giordano Nicoletti; Lorena Landuzzi; Manuel L Penichet; Tania Balboni; Marianna L Ianzano; Veronica Giusti; Thor G Theander; Morten A Nielsen; Ali Salanti; Pier-Luigi Lollini; Patrizia Nanni; Adam F Sander

doi:10.1080/2162402x.2017.1408749

Virus-like particle display of HER2 induces potent anti-cancer responses

Arianna Palladini, Susan Thrane, Christoph M Janitzek, Jessica Pihl, Stine B Clemmensen, Willem Adriaan de Jongh, Thomas M Clausen, Giordano Nicoletti, Lorena Landuzzi, Manuel L Penichet, Tania Balboni, Marianna L Ianzano, Veronica Giusti, Thor G Theander, Morten A Nielsen, Ali Salanti, Pier-Luigi Lollini, Patrizia Nanni, Adam F Sander

38 Citations (Scopus)

Abstract

Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20-30% of invasive breast cancers. Monoclonal antibody therapy is effective in treating HER2-driven mammary carcinomas, but its utility is limited by high costs, side effects and development of resistance. Active vaccination may represent a safer, more effective and cheaper alternative, although the induction of strong and durable autoantibody responses is hampered by immune-tolerogenic mechanisms. Using a novel virus-like particle (VLP) based vaccine platform we show that directional, high-density display of human HER2 on the surface of VLPs, allows induction of therapeutically potent anti-HER2 autoantibody responses. Prophylactic vaccination reduced spontaneous development of mammary carcinomas by 50%-100% in human HER2 transgenic mice and inhibited the growth of HER2-positive tumors implanted in wild-type mice. The HER2-VLP vaccine shows promise as a new cost-effective modality for prevention and treatment of HER2-positive cancer. The VLP platform may represent an effective tool for development of vaccines against other non-communicable diseases.

Original language	English
Article number	e1408749
Journal	OncoImmunology
Volume	7
Issue number	3
Number of pages	12
ISSN	2162-4011
DOIs	https://doi.org/10.1080/2162402x.2017.1408749
Publication status	Published - 4 Mar 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/2162402x.2017.1408749

2162402X.2017.1408749?needAccess=trueFinal published version, 1.69 MB

Cite this

Palladini, A., Thrane, S., Janitzek, C. M., Pihl, J., Clemmensen, S. B., de Jongh, W. A., Clausen, T. M., Nicoletti, G., Landuzzi, L., Penichet, M. L., Balboni, T., Ianzano, M. L., Giusti, V., Theander, T. G., Nielsen, M. A., Salanti, A., Lollini, P.-L., Nanni, P., & Sander, A. F. (2018). Virus-like particle display of HER2 induces potent anti-cancer responses. OncoImmunology, 7(3), Article e1408749. https://doi.org/10.1080/2162402x.2017.1408749

Palladini, A, Thrane, S , Janitzek, CM , Pihl, J , Clemmensen, SB, de Jongh, WA, Clausen, TM, Nicoletti, G, Landuzzi, L, Penichet, ML, Balboni, T, Ianzano, ML, Giusti, V, Theander, TG , Nielsen, MA , Salanti, A, Lollini, P-L, Nanni, P & Sander, AF 2018, 'Virus-like particle display of HER2 induces potent anti-cancer responses', OncoImmunology, vol. 7, no. 3, e1408749. https://doi.org/10.1080/2162402x.2017.1408749

@article{628bc5c17af44d73b1ae25dadd6e1223,

title = "Virus-like particle display of HER2 induces potent anti-cancer responses",

abstract = "Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20-30% of invasive breast cancers. Monoclonal antibody therapy is effective in treating HER2-driven mammary carcinomas, but its utility is limited by high costs, side effects and development of resistance. Active vaccination may represent a safer, more effective and cheaper alternative, although the induction of strong and durable autoantibody responses is hampered by immune-tolerogenic mechanisms. Using a novel virus-like particle (VLP) based vaccine platform we show that directional, high-density display of human HER2 on the surface of VLPs, allows induction of therapeutically potent anti-HER2 autoantibody responses. Prophylactic vaccination reduced spontaneous development of mammary carcinomas by 50%-100% in human HER2 transgenic mice and inhibited the growth of HER2-positive tumors implanted in wild-type mice. The HER2-VLP vaccine shows promise as a new cost-effective modality for prevention and treatment of HER2-positive cancer. The VLP platform may represent an effective tool for development of vaccines against other non-communicable diseases.",

author = "Arianna Palladini and Susan Thrane and Janitzek, {Christoph M} and Jessica Pihl and Clemmensen, {Stine B} and {de Jongh}, {Willem Adriaan} and Clausen, {Thomas M} and Giordano Nicoletti and Lorena Landuzzi and Penichet, {Manuel L} and Tania Balboni and Ianzano, {Marianna L} and Veronica Giusti and Theander, {Thor G} and Nielsen, {Morten A} and Ali Salanti and Pier-Luigi Lollini and Patrizia Nanni and Sander, {Adam F}",

year = "2018",

month = mar,

day = "4",

doi = "10.1080/2162402x.2017.1408749",

language = "English",

volume = "7",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Taylor & Francis",

number = "3",

}

TY - JOUR

T1 - Virus-like particle display of HER2 induces potent anti-cancer responses

AU - Palladini, Arianna

AU - Thrane, Susan

AU - Janitzek, Christoph M

AU - Pihl, Jessica

AU - Clemmensen, Stine B

AU - de Jongh, Willem Adriaan

AU - Clausen, Thomas M

AU - Nicoletti, Giordano

AU - Landuzzi, Lorena

AU - Penichet, Manuel L

AU - Balboni, Tania

AU - Ianzano, Marianna L

AU - Giusti, Veronica

AU - Theander, Thor G

AU - Nielsen, Morten A

AU - Salanti, Ali

AU - Lollini, Pier-Luigi

AU - Nanni, Patrizia

AU - Sander, Adam F

PY - 2018/3/4

Y1 - 2018/3/4

N2 - Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20-30% of invasive breast cancers. Monoclonal antibody therapy is effective in treating HER2-driven mammary carcinomas, but its utility is limited by high costs, side effects and development of resistance. Active vaccination may represent a safer, more effective and cheaper alternative, although the induction of strong and durable autoantibody responses is hampered by immune-tolerogenic mechanisms. Using a novel virus-like particle (VLP) based vaccine platform we show that directional, high-density display of human HER2 on the surface of VLPs, allows induction of therapeutically potent anti-HER2 autoantibody responses. Prophylactic vaccination reduced spontaneous development of mammary carcinomas by 50%-100% in human HER2 transgenic mice and inhibited the growth of HER2-positive tumors implanted in wild-type mice. The HER2-VLP vaccine shows promise as a new cost-effective modality for prevention and treatment of HER2-positive cancer. The VLP platform may represent an effective tool for development of vaccines against other non-communicable diseases.

AB - Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20-30% of invasive breast cancers. Monoclonal antibody therapy is effective in treating HER2-driven mammary carcinomas, but its utility is limited by high costs, side effects and development of resistance. Active vaccination may represent a safer, more effective and cheaper alternative, although the induction of strong and durable autoantibody responses is hampered by immune-tolerogenic mechanisms. Using a novel virus-like particle (VLP) based vaccine platform we show that directional, high-density display of human HER2 on the surface of VLPs, allows induction of therapeutically potent anti-HER2 autoantibody responses. Prophylactic vaccination reduced spontaneous development of mammary carcinomas by 50%-100% in human HER2 transgenic mice and inhibited the growth of HER2-positive tumors implanted in wild-type mice. The HER2-VLP vaccine shows promise as a new cost-effective modality for prevention and treatment of HER2-positive cancer. The VLP platform may represent an effective tool for development of vaccines against other non-communicable diseases.

U2 - 10.1080/2162402x.2017.1408749

DO - 10.1080/2162402x.2017.1408749

M3 - Journal article

C2 - 29399414

SN - 2162-4011

VL - 7

JO - OncoImmunology

JF - OncoImmunology

IS - 3

M1 - e1408749

ER -

Virus-like particle display of HER2 induces potent anti-cancer responses

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this